The NOX1/ NOX4 inhibitor setanaxib, which indirectly affects ENaC, is tested in clinical phase 2 and 3 trials for therapy of primary biliary cholangitis, liver stiffness and squamous cell carcinoma of the head and neck. This evidence concerns the gene NOX1 and primary biliary cholangitis.